Use of mitoxantrone-based combination chemotherapy regimens as first-line treatment for advanced breast cancer

W. R. Bezwoda, C. S. Hesdorffer, R. D. Dansey

Research output: Contribution to journalArticle

Abstract

Three first-line combination chemotherapy regimens which included mitoxantrone were studied for the treatment of advanced breast cancer. The first combination, consisting of methotrexate, mitoxantrone (Novantrone) and 5-fluoro-uracil (MNF), gave a response rate of 17/48 (35%). Cyclophosphamide + mitoxantrone (CN) gave a response rate of 20/31 (64%) while cyclophosphamide + mitoxantrone + vincristine (CNV) gave a response rate of 28/39 (72%). The response durations for the three regimens were 6 months for MNF, 7.5 months for CN and 11.5 months for CNV. The regimens were well tolerated with an approximately equal frequency of side-effects. Cardiotoxicity was infrequent, occurring in only 2 patients out of 118 studied.

Original languageEnglish (US)
Pages (from-to)465-467
Number of pages3
JournalSouth African Medical Journal
Volume72
Issue number7
StatePublished - Dec 1 1987

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Use of mitoxantrone-based combination chemotherapy regimens as first-line treatment for advanced breast cancer'. Together they form a unique fingerprint.

  • Cite this